Edding Genor Group Holdings (HKSE:06998) Net Margin %: 16.05% (As of Dec. 2025) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06998 Edding Genor Group Holdings Ltd HKSE:06998
15 GF Score
Price HK$1.53
! 1 Warning Sign
View Full Analysis

What is Edding Genor Group Holdings Net Margin %?

Edding Genor Group Holdings HKSE:06998 +0.33% 15 Net Margin % is 16.05% as of Dec. 2025, which is 3% above its 10-year median of 15.64. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 81.86% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Edding Genor Group Holdings's Net Income for the six months ended in Dec. 2025 was HK$441 Mil. Edding Genor Group Holdings's Revenue for the six months ended in Dec. 2025 was HK$2,748 Mil. Therefore, Edding Genor Group Holdings's net margin for the quarter that ended in Dec. 2025 was 16.05%.

The historical rank and industry rank for Edding Genor Group Holdings's Net Margin % or its related term are showing as below:

HKSE:06998' s Net Margin % Range Over the Past 10 Years
Min: 15.23   Med: 15.64   Max: 16.05
Current: 16.05


HKSE:06998's Net Margin % is ranked better than
81.86% of 959 companies
in the Drug Manufacturers industry
Industry Median: 5.53 vs HKSE:06998: 16.05

Edding Genor Group Holdings  (HKSE:06998) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Edding Genor Group Holdings Net Margin % Related Terms


Edding Genor Group Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Edding Genor Group Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edding Genor Group Holdings Net Margin % Chart

Edding Genor Group Holdings Annual Data
Trend Dec24 Dec25
Net Margin %
15.23 16.05

Edding Genor Group Holdings Semi-Annual Data
Dec24 Dec25
Net Margin % 15.23 16.05

HKSE:06998 vs ZTS: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edding Genor Group Holdings Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Edding Genor Group Holdings's Net Margin % falls into.


HKSE:06998
15GF Score
Edding Genor Group Holdings Ltd HKSE:06998
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edding Genor Group Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Edding Genor Group Holdings's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=441.076/2747.961
=16.05 %

Edding Genor Group Holdings's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=441.076/2747.961
=16.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 16.05% mean?
Edding Genor Group Holdings (HKSE:06998) has a Net Margin % of 16.05% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Edding Genor Group Holdings and its competitors. This is near median its historical median of 15.64. Over the past decade, Edding Genor Group Holdings' Net Margin % has ranged from 15.23 to 16.05. According to the industry distribution chart, Edding Genor Group Holdings ranks #174 out of 959 companies in the Drug Manufacturers industry, placing it in the top 18.1%.
Is Edding Genor Group Holdings' Net Margin % too high?
Edding Genor Group Holdings' current Net Margin % of 16.05% is near median its 10-year median of 15.64. Over the past 10 years, this metric has ranged from a low of 15.23 to a high of 16.05. The Drug Manufacturers industry median Net Margin % is 5.53. Edding Genor Group Holdings' value of 16.05% is 190.2% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #174 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #174 out of 959 companies for Net Margin %. This places Edding Genor Group Holdings in the top 18% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.53. Edding Genor Group Holdings' value of 16.05% is 190.2% above this benchmark. Historically, Edding Genor Group Holdings' own Net Margin % has ranged from 15.23 to 16.05 over the past decade. While the company's 10-year median is 15.64 vs. the industry median of 5.53, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.53, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current Net Margin % of 16.05% is 190.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current Net Margin % is 16.05%, which is near median its own 10-year median of 15.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current Net Margin % of 16.05%. The current Net Margin % is 16.05%, which is near median its 10-year median of 15.64 and 190.2% above the Drug Manufacturers industry median of 5.53. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current Net Margin % is 16.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edding Genor Group Holdings Business Description

Address No. 36 Doukou Road, Room 406, Building 1, Hengqin New Area, Guangdong Province, Zhuhai, CHN
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score

Get the complete analysis for HKSE:06998

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.53
Price